TEMALIEVA 100 mg contains Temozolomide, an oral alkylating chemotherapy agent. It works by methylating DNA, causing DNA damage and apoptosis of rapidly dividing tumor cells. Temozolomide crosses the blood–brain barrier, making it highly effective in treating brain tumors.

Temozolomide is indicated for treatment of:

1. Glioblastoma multiforme (GBM)
     – Newly diagnosed (with radiotherapy) and recurrent disease

2.  Anaplastic astrocytoma

3.  High-grade gliomas (as per oncologist protocol)

Common side effects:

•  Nausea and vomiting

•  Fatigue

•  Constipation or diarrhea

•  Headache

•  Loss of appetite

Hematological side effects:

•  Neutropenia

•  Thrombocytopenia

•  Anemia

Serious side effects:

•  Severe myelosuppression

•  Opportunistic infections (e.g., Pneumocystis jirovecii pneumonia)

•  Liver function abnormalities

Regular CBC and liver function tests are required.

Dosage is based on body surface area (BSA) and treatment phase.

Common regimens:

1. With radiotherapy (newly diagnosed GBM):

• 75 mg/m² once daily for 42 days

2. Adjuvant / maintenance therapy:

• 150–200 mg/m² once daily for 5 days every 28 days

100 mg strength is commonly used to achieve the calculated daily dose.


NOTE: This medicine should be taken only under a doctor’s supervision.